论文部分内容阅读
目的探讨多西他赛联合顺铂行食管癌辅助治疗的近期疗效。方法选择在我院接受术前多西他赛、顺铂联合辅助治疗的食管癌患者48例作为观察组,另选择同期采用常规手术治疗的食管癌患者48例作为对照组,比较两组手术治疗的总有效率、根治性切除率以及1年之后的生存率。结果观察组总有效率为60.4%,对照组总有效率为47.9%,差异有统计学意义(P<0.05)。观察组的根治性切除率为91.7%(44/48),对照组的根治性切除率为77.1%(37/48),差异有统计学意义(P<0.05)。术后1年生存率观察组明显高于对照组(P<0.05)。结论采用多西他赛联合顺铂行辅助化疗治疗食管癌可明显提高治疗效果及手术切除成功率,同时可以有效提高化疗患者术后1年的生存期,是一种有效治疗方法。
Objective To investigate the short-term effect of docetaxel combined with cisplatin in the adjuvant treatment of esophageal cancer. Methods Forty-eight patients with esophageal cancer who underwent preoperative docetaxel and cisplatin adjuvant therapy were selected as the observation group. Forty-eight patients with esophageal cancer who underwent routine surgery during the same period were selected as the control group. The surgical treatment was compared between the two groups The total effective rate, radical resection rate and survival rate after one year. Results The total effective rate was 60.4% in the observation group and 47.9% in the control group, the difference was statistically significant (P <0.05). The radical resection rate was 91.7% (44/48) in the observation group and 77.1% (37/48) in the control group, the difference was statistically significant (P <0.05). The 1-year postoperative survival rate was significantly higher in the observation group than in the control group (P <0.05). Conclusion Docetaxel combined with cisplatin adjuvant chemotherapy in the treatment of esophageal cancer can significantly improve the therapeutic effect and the success rate of surgical resection, and can effectively improve the survival of patients with chemotherapy after 1 year, is an effective treatment.